Tgf-Beta-Rezeptor-Typ-Ii-Varianten und Verwendungen davon
EP4775215
15. Juli 2026
Anmelder: Acceleron Pharma Inc. 🇺🇸
Details
- Veröffentlichungs-Nr.
- EP4775215
- Anmeldetag
- 21. August 2014
- Veröffentlichung
- 15. Juli 2026
- Rechtsraum
- EP
- IPC
- A61K38/00
Abstract
In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGFβ associated disorders.
Anmelder
- Firma
- Acceleron Pharma Inc.
- Land
- 🇺🇸 USA